Madopar

Levodopa and Benserazide, the active ingredient in Madopar, is a dopamine precursor and dopa decarboxylase inhibitor presented as an oral tablet for oral use. It is employed to manage the motor symptoms of Parkinson's disease and Parkinsonian syndrome in adult patients.

GNH USA supplies Madopar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Customers benefit from reliable logistics and comprehensive documentation for import clearance.

Madopar acts on the dopaminergic pathway and is indicated for Parkinsonian disorders.

Parkinson's disease: improves motor function and reduces rigidity and bradykinesia. Parkinsonian syndrome: alleviates tremor and stiffness associated with secondary parkinsonism. Early-stage Parkinson's disease: provides symptomatic relief to maintain daily activities.

Madopar may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Nausea and vomiting - Dizziness or light‑headedness - Orthostatic hypotension - Headache - Insomnia - Dry mouth

Serious or Rare Side Effects: - Dyskinesia (involuntary movements) - Hallucinations or other psychiatric disturbances - Severe hypotension or cardiac arrhythmia

When prescribing Madopar, clinicians should observe several precautionary measures to ensure safe use.

Monitor blood pressure: watch for orthostatic hypotension, especially at treatment initiation. Assess for dyskinesia: adjust dose if involuntary movements develop. Review concomitant MAO‑B inhibitors: avoid combined use due to risk of hypertensive crisis. Adjust dose in renal impairment: reduced clearance may increase plasma levels. Avoid abrupt discontinuation: taper gradually to prevent withdrawal symptoms. Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Madopar interacts with several medicines; some combinations must be avoided while others require careful monitoring.

Major Interactions (Avoid): - Non‑selective MAO inhibitors (e.g., phenelzine): can cause severe hypertensive reactions. - Antipsychotics that block dopamine receptors (e.g., haloperidol): reduce therapeutic effect and may precipitate neuroleptic malignant syndrome.

Moderate Interactions (Monitor Closely): - Iron or calcium supplements: decrease levodopa absorption; separate dosing by at least 2 hours. - High‑protein meals: compete with levodopa transport, potentially lowering efficacy. - Anticholinergic agents (e.g., benztropine): may increase central side effects such as confusion.